MMP-1 expression has an independent prognostic value in breast cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Boström, Pia ^a   Söderström, Mirva ^a   Vahlberg, Tero ^b   Söderström, Karl Ove ^a   Roberts, Peter J ^a   Carpén, Olli ^a   Hirsimäki, Pirkko ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; PROSTAGLANDIN RECEPTOR; PROTEIN BCL 2; PROTEIN P53; ERBB2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STROMA CELL; SURVIVAL RATE; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; ENZYMOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051499222     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-348     Document Type: Article

References (36)

1. WHO Women's health. 2009, Fact sheet No 334, WHO.
2. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipides T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa CD, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 2006, 17:1504-1511. 10.1093/annonc/mdl147, 16968874.
3. Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 Protein Expression and Long-Term Survival in Breast Cancer. Am J Pathol 1994, 145:1191-1198. 1887415, 7977649.
4. Martinez-Arribas F, Alvarez T, Del Val G, Martin-Garabato E, Nunez-Villar MJ, Lucas R, Sanchez J, Tejerina A, Schneider J. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res 2007, 27:219-222.
5. Ellis P, Schnitt S, Sastre-Garau X, Bussolati G, Tavassoli F, Eusebi V, Peterse J, Mukai K, Tabar L, Jacquemier J, Cornelisse C, Sasco A, Kaaks R, Pisani P, Goldgar D, Devilee P, Cleton-Jansen M, Borresen-Dale A, van't Veer L, Sapino A. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, 9-59. Lyon, Tavassoli FA & Devilee P.
6. Perou C, Sørlie T, Elsen M, van de Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L, Fluge T, Pergamenschlkov A, Williams C, Zhu S, Lønning P, Børresen-Dale A-L, Brown P, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
7. Sørlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botstein D, Lønning P, Børresen-Dale A-L. Gene expression patterns of breast carcinomas distuinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
8. Foulkes W, Smith I, Reis-Filho J. Triple-Negative Breast Cancer. N Engl J Med 2010, 363:1938-1948. 10.1056/NEJMra1001389, 21067385.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
10. García M, González-Reyes S, González L, Junquera S, Berdize N, Del Casar J, Medina M, Vizoso F. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Path 2010, 91:324-334.
11. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 2006, 69:562-573. 10.1016/j.cardiores.2005.12.002, 16405877.
12. Hesek D, Toth M, Meroueh S, Brown S, Zhao H, Sakr W, Fridman R, Mobashery S. Design and Characterization of a Metalloproteinase Inhibitor-Tethered Resin for the Detection of Active MMPs in Biological Samples. Chemistry & Biology 2006, 13:379-386. 10.1016/j.chembiol.2006.01.012, 21837812.
13. Deryugina E, Quigley J. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34. 10.1007/s10555-006-7886-9, 16680569.
14. Del Casar J, González-Reyes S, González L, González J, Junquera S, Bongera M, García M, Andicoechea A, Serra C, Vizoso F. Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol 2010, 136:811-819. 10.1007/s00432-009-0721-2, 19916023.
15. Roy R, Yang J, Moses M. Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer. J Clin Oncol 2009, 27:5287-5297. 10.1200/JCO.2009.23.5556, 2773480, 19738110.
16. Zhou P, Du LF, Lv GQ, Yu XM, Gu YL, Li JP, Zhang C. Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011, 127:813-818. 10.1007/s10549-010-1294-0, 21161369.
17. Vihinen P, Kähäri V-M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99:157-166. 10.1002/ijc.10329, 11979428.
18. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174. 10.1038/nrc745, 11990853.
19. Brinckerhoff C, Rutter J, Benbow U. Interstitial Collagenases as Markers of Tumor Progression. Clin Cancer Res 2000, 6:4823-4830.
20. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008, 19:1566-1572. 10.1093/annonc/mdn180, 18503039.
21. Minn A, Gupta G, Siegel P, Bos P, Shu W, Giri D, Viale A, Olshen A, Gerald W, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
22. Eck S, Hoopes P, Petrella B, Coon C, Brinckerhoff C. Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 2009, 116:79-90. 10.1007/s10549-008-0085-3, 18597171.
23. Vizoso FJ, Gonzáles LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007, 96:903-911. 10.1038/sj.bjc.6603666, 2360108, 17342087.
24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
25. Boström P, Söderström M, Palokangas T, Vahlberg T, Collan Y, Carpen O, Hirsimäki P. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes 2009, 2:140. 10.1186/1756-0500-2-140, 2716358, 19615042.
26. Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009, 9:188. 10.1186/1471-2407-9-188, 2706257, 19531263.
27. Heppner K, Matrisian L, Jensen R, Rodgers W. Expression of Most Matrix Metalloproteinase Family Members in Breast Cancer Represents a Tumor-Induced Host Response. Am J Pathol 1996, 149:273-282. 1865221, 8686751.
28. Baker E, Stephenson T, Reed M, Brown N. Expression of proteinases and inhibitors in human breast cancer progression and survival. J Clin Pathol: Mol Pathol 2002, 55:300-304.
29. Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris P. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999, 30:436-442. 10.1016/S0046-8177(99)90120-X, 10208466.
30. Duffy M, Maguire T, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2:252-257. 10.1186/bcr65, 138784, 11250717.
31. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J. Polymorphismus of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cacer Res Treat 2006, 95:65-72.
32. Coussens L, Fingleton B, Matrisian L. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science 2002, 295:2387-2392. 10.1126/science.1067100, 11923519.
33. González L, Corte M, Vázquez J, Junquera S, Sanchez R, Alvarez A, Rodriguez J, Lamelas M, Vizoso F. Androgen receptor expression in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008, 8:149. 10.1186/1471-2407-8-149, 2416360, 18507821.
34. Soerjomataram I, Louwman M, Ribot J, Roukema J, Coebergh J. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008, 107:309-330. 10.1007/s10549-007-9556-1, 2217620, 17377838.
35. Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J-I, Miyamoto M, Hirano S, Kondo S, Moriuchi T. High MMP-1 mRNA Expression is a Risk Factor for Disease-Free and Overall Survivals in Patients with Invasive Breast Carcinoma. J Surgical Res 2008, 146:104-109.
36. González L, Corte M, Junquera S, González-Fernández R, del Casar J, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso F. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Human Pathol 2009, 40:1224-1233.